Checkpoint inhibitors in metastatic renal cell carcinoma patients including elderly subgroups: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Steven Yip(University of Calgary), Daniel Yick Chin Heng(University of Calgary), Brian I. Rini(Vanderbilt University Medical Center), Naveen S. Basappa, Hao‐Wen Sim(The University of Sydney), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Ravindran Kanesvaran(University of Ioannina), Anil Kapoor(People’s University), Alex H.C. Wong(University of Alberta), D. Scott Ernst, Lori Wood(Dalhousie University), Raphael Brandão Moreira(Dana-Farber Cancer Institute), Simon Fu(BC Cancer Agency), Takeshi Yuasa(Japanese Foundation For Cancer Research), Christina M. Canil(University of Ottawa), Sandy Srinivas(Stanford University), Toni K. Choueiri(Harvard University), Camillo Porta(University of Pavia)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k